UroGen Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Strong Q4 results and a permanent J-code have accelerated adoption and revenue, with ZUSDURI now outpacing JELMYTO in key metrics. Debt refinancing enhances flexibility for R&D, while pipeline assets like UGN-103 and UGN-501 are advancing toward major milestones.
-
RTGel enables sustained drug delivery for urothelial cancers, with ZUSDURI recently approved for a large bladder cancer market. Early launch shows strong revenue growth and physician enthusiasm, with ZUSDURI positioned as a non-surgical, chemoablative option and billion-dollar potential.
Fiscal Year 2025
-
ZUSDURI's launch drove a 21% revenue increase in 2025, with accelerated adoption after a permanent J-code and strong pipeline progress. Financial flexibility improved with a $250 million refinancing, while JELMYTO continued steady growth.
-
The company is advancing its innovative RTGel-based therapies for urothelial cancers, with ZUSDURI recently approved as the first non-surgical option for intermediate-risk NMIBC. Market adoption is expected to accelerate in 2025 with the introduction of a permanent J-code, while next-generation products and strong IP protection support long-term growth.
-
RTGel technology enables extended drug delivery for urologic cancers, with Zusduri recently launched for intermediate-risk NMIBC. Early adoption is strong, with significant revenue growth and robust demand. Reimbursement improvements and a strong pipeline, including UGM-103 and an oncolytic virus, support long-term growth.
-
ZUSDURI launch is gaining momentum with strong physician interest and growing patient enrollment, though operational and reimbursement hurdles are delaying broader adoption until the permanent J code takes effect in 2026. JELMYTO continues to deliver steady revenue growth and remains a standard of care.
-
RTGel technology enables non-surgical, office-based therapies for urothelial cancers, with Zosduri recently FDA-approved for a large patient population. Early launch shows strong physician enthusiasm, robust demand, and broad market access. Pipeline includes next-gen products and immunotherapy, with solid cash reserves supporting growth.
-
RTGel technology underpins two key products: Jelmyto, a kidney-sparing therapy for upper tract urothelial cancer, and Zosduri, a primary therapy for intermediate-risk NMIBC with strong clinical results. Zosduri targets a $5B+ market, with broad adoption expected after J-code implementation and a robust commercial infrastructure in place.
-
Management highlighted a large market opportunity for its new bladder cancer therapy, emphasizing strong clinical durability, a robust commercial rollout, and the importance of permanent J code reimbursement for adoption. Pipeline advances, including next-generation and high-grade disease products, support long-term growth.
-
The meeting featured the launch of a new FDA-approved therapy expected to drive significant growth, approval of all six board proposals, and the election of directors. No shareholder questions were raised, and final voting results will be reported soon.
-
FDA approval and launch of ZUSDURI mark a major milestone, targeting a $5B+ market with strong early physician and payer interest. Jelmyto revenues grew 11% year-over-year, and the company maintains robust cash reserves to support ongoing launches and R&D.
-
ZUSDURI received FDA approval for recurrent low-grade non-muscle invasive bladder cancer, supported by strong phase 3 data showing high response rates and durable benefit. Launch is set for July 1 with a $21,500 per vial price, targeting early adopters and a large Medicare population.
-
ODAC discussions on UGN-102 were dominated by calls for randomized trials, leading to a split vote despite strong efficacy and safety data. The company is pursuing multiple regulatory paths, including post-marketing studies, and continues to engage with the FDA ahead of the June 13 PDUFA date.
-
UGN-102 is nearing FDA approval with strong clinical data and a $5B+ market opportunity, while JELMYTO Q1 sales grew 8% year-over-year. The company maintains robust liquidity and is expanding its commercial infrastructure in anticipation of UGN-102's launch.
-
UGN-102 is positioned for a pivotal year, with strong phase III data supporting FDA review and a potential June approval. Launch preparations are robust, targeting both academic and community adoption, while the pipeline expands into high-grade disease. Patent protection and market opportunity support long-term growth.
-
The update highlights progress on UGN-102, next-gen formulations, and the acquisition of ICVB-1042, a selective oncolytic virus for cancer. Early data and favorable financial terms support its development, with IND-enabling studies planned and a focus on local delivery.
-
Significant progress was highlighted in advancing therapies for non-muscle invasive bladder cancer, with UGN-102 showing strong efficacy and safety data and a major FDA decision expected in June. Commercial and pipeline strategies are supported by robust financials and patent protection.
-
RTGel technology enables sustained drug delivery for urothelial cancers, with JELMYTO reducing kidney loss and showing strong real-world outcomes. UGN-102, targeting a larger market, demonstrated high response and durability in trials and is under FDA review, with commercial launch preparations underway.
Fiscal Year 2024
-
UGN-102 NDA submitted ahead of schedule, with FDA review and a June 2025 PDUFA date; Jelmyto revenues grew 9% to $90.4M in 2024. UGN-102 targets a $5B+ market, and commercial expansion is underway, supported by a strong $241.7M cash position.
-
RTGel technology enables prolonged drug delivery for urothelial cancers, with JELMYTO showing strong demand and UGN-102 poised for a major market expansion pending FDA review. Patent extensions and next-gen products aim to secure long-term exclusivity, while early-stage programs target future growth.
-
FDA accepted the NDA for UGN-102, targeting a $5B market, with a PDUFA date of June 13, 2025. Jelmyto Q3 revenue grew 21% year-over-year, and the company is preparing for a major commercial launch, supported by a strong cash position and expanded leadership.
-
The company is advancing UGN-102 for low-grade NMIBC, supported by strong clinical data and a large market opportunity. With an NDA submitted and a potential FDA decision by early 2024, commercial preparations are underway, targeting over $1 billion in sales.
-
A novel drug delivery platform is advancing non-surgical therapies for urothelial cancers, with UGN-102 showing strong clinical results and a large market opportunity. Regulatory filings are underway, commercialization plans are robust, and the company is financially positioned for growth.
-
Strong ENVISION data for UGN-102 supports imminent NDA submission and potential Q1 2025 approval, targeting a large market. Jelmyto Q2 revenue grew 16% sequentially, but headwinds persist. Cash position of $241.3M supports launch and pipeline advancement.
-
The ENVISION phase 3 study of UGN-102 in low-grade, intermediate-risk NMIBC showed a 79.6% complete response rate at 3 months and 82.3% of responders remained disease-free at 12 months. UGN-102 was well-tolerated, had less impact on daily life than surgery, and is seen as a potential paradigm shift in treatment.
-
RTGel technology enables longer-acting therapies for urothelial cancers, with Jelmyto showing steady growth and UGN-102 poised for regulatory submission following strong clinical data. UGN-102 is expected to launch next year, supported by expanded sales and robust patient/physician preference.